# Tumor Lysis Syndrome

Tumor lysis syndrome requires prospective risk stratification before cytoreduction, intensive early metabolic surveillance, rapid urate reduction when indicated, and a low threshold for renal replacement therapy when electrolyte derangements, oliguria, or volume overload become refractory.

**Clinical question:** How should physicians identify, prevent, monitor, and urgently manage tumor lysis syndrome in patients receiving anticancer therapy?

Updated: 2026-08-20T23:35:50.928681Z

## What matters in practice
- Assess TLS risk before therapy using tumor burden, proliferative rate, anticipated treatment sensitivity, baseline kidney function, volume status, and baseline urate and electrolyte abnormalities. [19][21]
- Clinical TLS is a metabolic emergency: rapidly address hyperkalemia, hyperphosphatemia, acute kidney injury, arrhythmia risk, and volume status while initiating urate-lowering therapy and nephrology involvement. [19][21]
- Rasburicase degrades existing uric acid and is favored for high-risk patients or established hyperuricemic TLS; avoid it in known G6PD deficiency because hemolysis and methemoglobinemia can occur. [18][19]
- Do not routinely alkalinize urine in TLS; it can promote calcium-phosphate precipitation and worsen kidney injury. [18][19]
- Early rasburicase within 12 hours of established TLS was associated with lower in-hospital kidney replacement therapy or death in a multicenter U.S. target-trial emulation; residual confounding remains possible. [4]

## Identify patients needing intensive prophylaxis

TLS prevention begins before the first cytoreductive dose, including corticosteroids, targeted agents, cellular therapy, or radiation.

TLS results from spontaneous or treatment-related release of intracellular potassium, phosphate, and nucleic acids. Uric acid generation and calcium-phosphate deposition can contribute to acute kidney injury (AKI); hyperkalemia and hypocalcemia can cause arrhythmias or seizures. [19][21]

Risk is driven by disease burden, cellular proliferation and turnover, treatment sensitivity, and patient-specific clearance limitations. Large burden may include leukocytosis, bulky disease, organ infiltration, or markedly elevated lactate dehydrogenase; preexisting kidney dysfunction, dehydration, hyperuricemia, and nephrotoxin exposure increase the risk that laboratory lysis progresses to clinical TLS. [4][19][21]

Novel targeted, immune-based, and cellular therapies have made TLS less predictable than in the conventional cytotoxic chemotherapy era. Risk assessment should therefore be regimen-specific and repeated when disease burden or treatment intensity changes. [17][21]
- Obtain baseline potassium, phosphate, calcium, creatinine, uric acid, and lactate dehydrogenase before therapy in patients at risk; obtain an ECG when hyperkalemia or clinically significant electrolyte disturbance is present or anticipated. [16][21]
- Use prophylactic IV hydration in intermediate- or high-risk patients when cardiopulmonary status permits; monitor intake, urine output, weight, and congestion because fluid overload may worsen outcomes. [17][19][21]
- Avoid potassium and phosphate supplementation unless there is a compelling indication. [19]
- Do not use sodium bicarbonate solely to alkalinize urine for TLS prevention or treatment. [18][19]

*Risk-directed prophylaxis and surveillance principles. Specific institutional protocols should define fluid rates, monitoring frequency, and site of care. [19][21]*

| Risk context | Initial prevention approach | Monitoring and disposition |
| --- | --- | --- |
| Lower anticipated TLS risk | Assess baseline renal function and metabolic profile; ensure hydration and arrange repeat laboratory testing appropriate to the regimen. [19][21] | Outpatient monitoring may be appropriate only when disease, regimen, renal function, and reliable follow-up support it. [21] |
| Intermediate risk or impaired renal reserve | IV hydration when feasible; use a xanthine oxidase inhibitor for urate prevention when indicated; escalate to rasburicase if hyperuricemia develops or clinical/laboratory TLS emerges. [19] | Serial electrolytes, uric acid, and kidney function during the risk window; increase monitoring and level of care for evolving abnormalities. [19][21] |
| High risk or established TLS | IV hydration with careful volume assessment plus rasburicase when not contraindicated; involve nephrology early. [19][21] | Frequent laboratory and cardiac surveillance; inpatient management is generally required because metabolic deterioration can be rapid. [16][19][21] |

## Diagnose laboratory and clinical TLS while excluding mimics

Treat the patient’s metabolic trajectory, not a single laboratory value in isolation.

The Cairo-Bishop framework classifies laboratory TLS by abnormalities in uric acid, potassium, phosphate, and calcium occurring around treatment initiation; clinical TLS requires laboratory TLS plus a clinically important complication such as AKI, arrhythmia, seizure, or sudden death. Adult absolute laboratory thresholds cited in contemporary reviews include uric acid at least 8 mg/dL, potassium at least 6 mEq/L, and phosphate at least 4.5 mg/dL; calcium decline is a supporting abnormality. [19][20]

Interpret criteria in context. Baseline chronic kidney disease, pseudohyperkalemia, phosphate administration, hypocalcemia from other causes, sepsis-associated AKI, and obstructive uropathy can mimic or compound TLS. The central clinical question is whether rapid tumor-cell breakdown is producing a worsening metabolic pattern that exceeds renal clearance. [19][21]

Spontaneous TLS occurs, particularly with high tumor burden, and should be considered before therapy when hyperuricemia accompanies hyperkalemia, hyperphosphatemia, AKI, oliguria, or rapidly rising lactate dehydrogenase. [4][18][21]
- Obtain serial potassium, phosphate, calcium, creatinine, uric acid, bicarbonate, and lactate dehydrogenase; monitor urine output and fluid balance. [19][21]
- Use continuous or repeated ECG assessment for meaningful hyperkalemia, conduction abnormalities, or arrhythmic symptoms. [14][16][21]
- New oliguria, pulmonary edema, rising creatinine, persistent hyperphosphatemia, tetany, seizure, syncope, or arrhythmia should trigger immediate escalation rather than waiting for complete diagnostic classification. [16][19][21]

*Metabolic pattern and immediate clinical consequence in TLS. [16][19][21]*

| Abnormality | Major consequence | Immediate priority |
| --- | --- | --- |
| Hyperkalemia | Potentially fatal conduction disturbance or arrhythmia. [16][19] | ECG assessment, cardiac membrane stabilization and intracellular shifting when indicated, potassium removal, and dialysis for refractory disease. [19] |
| Hyperphosphatemia with secondary hypocalcemia | Calcium-phosphate deposition, AKI, tetany, seizures, and arrhythmia. [16][19] | Restrict phosphate exposure, consider phosphate binders, treat symptomatic hypocalcemia cautiously, and use renal replacement therapy when refractory or severe. [19][21] |
| Hyperuricemia | Urate crystal and noncrystal-mediated kidney injury. [4][19][21] | Hydration when tolerated and rapid urate lowering; rasburicase lowers existing urate. [19] |
| AKI or oliguria | Reduced clearance amplifies all TLS abnormalities and limits safe hydration. [19][21] | Early nephrology consultation and a lower threshold for renal replacement therapy. [19][21] |

## Choose allopurinol or rasburicase by urgency and urate burden

Xanthine oxidase inhibition prevents new uric acid formation; urate oxidase removes uric acid already present.

Allopurinol and febuxostat reduce uric acid production by inhibiting xanthine oxidase but do not remove preformed uric acid. Their greatest role is prophylaxis in patients who can start therapy before substantial hyperuricemia develops. Rasburicase enzymatically converts uric acid to allantoin and can rapidly lower existing uric acid; it is preferred for high-risk patients or established TLS with hyperuricemia when no contraindication exists. [19][21]

The supplied sources describe traditional rasburicase dosing of 0.15 to 0.20 mg/kg IV daily for up to 7 days, but they also note contemporary practice variation, including reduced-dose strategies that have not been uniformly tested in randomized trials. Follow current institutional protocol and product labeling for dosing, repeat dosing, and laboratory specimen handling. [18][21]

Do not administer rasburicase to patients with known G6PD deficiency. Hemolytic anemia and methemoglobinemia are rare but serious adverse events related to oxidative stress from hydrogen peroxide generation. When feasible, screen patients at increased likelihood of G6PD deficiency before treatment; in life-threatening TLS, the urgency of treatment requires individualized risk-benefit assessment. [18][19]
- If rasburicase is used, ensure local laboratory handling prevents ex vivo uric acid degradation; older guidance recommends transport of samples on ice. [18]
- Allopurinol requires renal-dose consideration in kidney impairment; the supplied evidence does not provide a current adult dosing regimen. [18]
- Avoid relying on allopurinol alone to rapidly correct established marked hyperuricemia. [18][19]
- Monitor for persistent hyperphosphatemia even when uric acid normalizes; contemporary reviews emphasize that phosphate-related nephrotoxicity may predominate after widespread rasburicase use. [17][21]

*Urate-lowering agent selection in TLS. [18][19][21]*

| Agent | Clinical role | Key limitation or safety issue |
| --- | --- | --- |
| Allopurinol | Prevents formation of new uric acid; most useful as prophylaxis before major urate accumulation. [18][19] | Does not reduce uric acid already formed; may permit xanthine accumulation; dose adjustment is needed with renal impairment. [18] |
| Febuxostat | Alternative xanthine oxidase inhibitor for urate prevention. [19] | The supplied sources do not provide dosing or comparative selection criteria for acute TLS. [19] |
| Rasburicase | Rapidly degrades existing uric acid; favored in high-risk patients or hyperuricemic established TLS. [18][19] | Contraindicated in known G6PD deficiency; may cause hemolysis or methemoglobinemia. [18][19] |

## Manage TLS as a time-sensitive multisystem emergency

Parallel treatment of electrolyte abnormalities, kidney injury, and the cause of ongoing tumor lysis is required.

Admit patients with established or evolving clinical TLS for close monitoring. Treat hyperkalemia according to severity and ECG findings, restrict exogenous potassium and phosphate, manage volume carefully, and use urate-lowering therapy appropriate to urate burden and contraindications. [19][21]

Treat symptomatic hypocalcemia, such as tetany, seizure, or arrhythmia, but avoid routine calcium replacement for asymptomatic biochemical hypocalcemia because added calcium can increase calcium-phosphate precipitation. The primary strategy is control of phosphate burden and restoration of renal clearance. [18][19]

Renal replacement therapy indications are broadly similar to other causes of AKI but the threshold is lower in TLS because solute release can be rapid and persistent. Refractory hyperkalemia, persistent severe hyperphosphatemia, symptomatic hypocalcemia attributable to phosphate excess, oliguria or anuria, uncontrolled volume overload, severe acidosis, and uremic complications should prompt urgent nephrology-directed dialysis. [18][19][21]
- Obtain nephrology consultation promptly for oliguria, rising creatinine, refractory phosphate elevation, or inability to safely continue hydration. [18][19]
- Use dialysis modality according to hemodynamic stability and expected solute burden; the supplied evidence notes that continuous therapies may be used in unstable patients, while ongoing rapid lysis may require repeated clearance. [18]
- Search for and correct contributors to AKI, including hypovolemia, nephrotoxins, obstruction, sepsis, and contrast exposure. [19][21]

### Timing of rasburicase in established TLS

In a 36-hospital U.S. observational target-trial emulation of 1,276 adults with established TLS, rasburicase administered within 12 hours of TLS onset was associated with lower in-hospital kidney replacement therapy or death than delayed or no early rasburicase (32.7% vs 42.0%; adjusted odds ratio, 0.67). The study also found lower 90-day mortality (adjusted odds ratio, 0.71). This is clinically important but remains observational evidence subject to residual confounding; it supports prompt therapy rather than proving causality. [4]

*Escalation triggers in established TLS. [18][19][21]*

| Finding | Action |
| --- | --- |
| Potassium elevation with ECG abnormality, severe elevation, or inadequate response to temporizing therapy | Treat as an emergency and arrange urgent renal replacement therapy when refractory. [18][19] |
| Persistent hyperphosphatemia with worsening AKI or symptomatic hypocalcemia | Restrict phosphate, consider binders, avoid routine calcium if asymptomatic, and initiate renal replacement therapy when refractory. [18][19][21] |
| Oliguria or anuria, pulmonary edema, or inability to hydrate safely | Urgent nephrology involvement and renal replacement therapy assessment. [18][19] |
| Clinical deterioration after treatment begins | Reassess for ongoing tumor lysis, infection, obstruction, medication toxicity, and alternative causes of metabolic derangement. [19][21] |

## Anticipate TLS beyond classic leukemia and lymphoma

Solid tumors and modern therapies can produce TLS when tumor burden and treatment response are substantial.

TLS is most common in rapidly proliferating hematologic malignancies with high tumor burden, but it also occurs in solid tumors and after targeted therapy. A reported case of lenvatinib-associated TLS in hepatocellular carcinoma illustrates that clinically important TLS can occur after noncytotoxic targeted therapy; case reports establish signal recognition, not incidence or routine prophylaxis requirements. [14][16]

For patients receiving new therapies, determine whether the regimen label, disease-specific guideline, or institutional pathway has a mandated step-up schedule, hydration plan, laboratory schedule, or inpatient observation requirement. General TLS principles remain applicable, but the risk window and pace of lysis may differ by agent. [17][21]
- Do not dismiss TLS because therapy is oral, targeted, immunologic, or palliative. [14][17][21]
- Reassess risk after debulking, before escalation, and whenever kidney function worsens or baseline urate rises. [19][21]

## Common questions

### When should rasburicase be used instead of allopurinol?

Use rasburicase when rapid reduction of existing uric acid is needed, particularly in high-risk patients or established hyperuricemic TLS. Allopurinol prevents new uric acid formation but does not remove urate already present. [18][19]

### Should urine alkalinization be used in TLS?

No. Routine urine alkalinization is not recommended because it lacks demonstrated benefit and can promote calcium-phosphate deposition and xanthine precipitation, worsening renal injury. [18][19]

### What is the practical dialysis threshold in TLS?

Use a lower threshold than in routine AKI when rapid solute release is ongoing. Refractory hyperkalemia, severe or persistent hyperphosphatemia, symptomatic hypocalcemia from phosphate excess, oliguria or anuria, uncontrolled volume overload, severe acidosis, or uremic complications warrant urgent nephrology-directed renal replacement therapy. [18][19][21]

### Can TLS occur spontaneously or in solid tumors?

Yes. TLS may precede therapy in patients with high tumor burden and can occur in solid tumors or with modern targeted therapies when cellular destruction is rapid. [4][14][18][21]

## References
1. - IIER - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf
2. Food and Drug Administration — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s025lbl.pdf
3. FDA Label Search-Package Code — labels.fda.gov — https://labels.fda.gov/packagecode.cfm
4. Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial | The BMJ — www.bmj.com — https://www.bmj.com/content/394/bmj-2026-100040
5. Spontaneous tumour lysis syndrome in chronic lymphocytic ... — casereports.bmj.com — https://casereports.bmj.com/content/17/11/e261320
6. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy | Journal for ImmunoTherapy of Cancer — jitc.bmj.com — https://jitc.bmj.com/content/12/2/e008735
7. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S2352-3026(21)00307-0/attachment/9cfba348-95ce-48e8-855a-ec590eaf8407/mmc1.pdf
8. Spontaneous Tumor Lysis Syndrome Secondary to ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/aimcc.2024.0871
9. Abstract 18257: Arrhythmias in Tumor Lysis Syndrome — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.18257
10. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0b013e3181d4739e
11. Contemporary Diagnosis and Management of Patients ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000670
12. Guidelines for the Early Management of Patients With ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/str.0b013e318284056a
13. FDA-approved heterocyclic molecules for cancer treatment — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(23)10380-X
14. Lenvatinib-Induced Tumor Lysis Syndrome in... : ACG Case Reports Journal — journals.lww.com — https://journals.lww.com/acgcr/fulltext/2023/09000/lenvatinib_induced_tumor_lysis_syndrome_in.7.aspx
15. Tumor Lysis Syndrome: Pathophysiology, Risk Factors, ... — journals.lww.com — https://journals.lww.com/japa/_layouts/15/oaks.journals/downloadpdf.aspx?an=02276274-202307000-00003
16. Tumor Lysis Syndrome : Critical Care Nurse — journals.lww.com — https://journals.lww.com/00003242-202206000-00003
17. Tumor Lysis Syndrome : New England Journal of Medicine — journals.lww.com — https://journals.lww.com/00006024-202509180-00008
18. Tumor Lysis Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/tumor-lysis-syndrome
19. Tumor Lysis Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1548559521000963
20. Review article Tumor lysis syndrome in gynecologic cancers — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352578919301031
21. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0305737223000968
22. British Journal of Haematology — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.70092
23. British Society for Haematology Updated Guidelines for the ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.70092
24. An Unusual Presentation of Tumor Lysis Syndrome in a ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2012/468452

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.